The global AI in pharmaceutical market size is calculated at USD 1.94 billion in 2025 and is forecasted to reach around USD 16.49 billion by 2034, accelerating at a CAGR of 27% from 2025 to 2034. The North America AI in pharmaceutical market size surpassed USD 530 million in 2024 and is expanding at a CAGR of 27.14% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: AI in Pharmaceutical Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. AI in Pharmaceutical Market, by Technology Type,
8.1.1. Natural Language Processing
8.1.1.1. Market Revenue and Forecast
8.1.2. Context-Aware Processing
8.1.2.1. Market Revenue and Forecast
8.1.3. Deep Learning
8.1.3.1. Market Revenue and Forecast
8.1.4. Querying Method
8.1.4.1. Market Revenue and Forecast
9.1. AI in Pharmaceutical Market, by Application,
9.1.1. Drug Discovery
9.1.1.1. Market Revenue and Forecast
9.1.2. Clinical Trial
9.1.2.1. Market Revenue and Forecast
9.1.3. Research & Development
9.1.3.1. Market Revenue and Forecast
9.1.4. Others
9.1.4.1. Market Revenue and Forecast
10.1. AI in Pharmaceutical Market, by Drug,
10.1.1. Large Molecules
10.1.1.1. Market Revenue and Forecast
10.1.2. Small Molecules
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology
11.1.2. Market Revenue and Forecast, by Application
11.1.3. Market Revenue and Forecast, by Drug
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology
11.1.4.2. Market Revenue and Forecast, by Application
11.1.4.3. Market Revenue and Forecast, by Drug
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology
11.1.5.2. Market Revenue and Forecast, by Application
11.1.5.3. Market Revenue and Forecast, by Drug
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology
11.2.2. Market Revenue and Forecast, by Application
11.2.3. Market Revenue and Forecast, by Drug
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology
11.2.4.2. Market Revenue and Forecast, by Application
11.2.4.3. Market Revenue and Forecast, by Drug
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology
11.2.5.2. Market Revenue and Forecast, by Application
11.2.5.3. Market Revenue and Forecast, by Drug
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology
11.2.6.2. Market Revenue and Forecast, by Application
11.2.6.3. Market Revenue and Forecast, by Drug
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology
11.2.7.2. Market Revenue and Forecast, by Application
11.2.7.3. Market Revenue and Forecast, by Drug
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology
11.3.2. Market Revenue and Forecast, by Application
11.3.3. Market Revenue and Forecast, by Drug
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology
11.3.4.2. Market Revenue and Forecast, by Application
11.3.4.3. Market Revenue and Forecast, by Drug
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology
11.3.5.2. Market Revenue and Forecast, by Application
11.3.5.3. Market Revenue and Forecast, by Drug
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology
11.3.6.2. Market Revenue and Forecast, by Application
11.3.6.3. Market Revenue and Forecast, by Drug
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology
11.3.7.2. Market Revenue and Forecast, by Application
11.3.7.3. Market Revenue and Forecast, by Drug
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology
11.4.2. Market Revenue and Forecast, by Application
11.4.3. Market Revenue and Forecast, by Drug
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology
11.4.4.2. Market Revenue and Forecast, by Application
11.4.4.3. Market Revenue and Forecast, by Drug
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology
11.4.5.2. Market Revenue and Forecast, by Application
11.4.5.3. Market Revenue and Forecast, by Drug
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology
11.4.6.2. Market Revenue and Forecast, by Application
11.4.6.3. Market Revenue and Forecast, by Drug
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology
11.4.7.2. Market Revenue and Forecast, by Application
11.4.7.3. Market Revenue and Forecast, by Drug
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology
11.5.2. Market Revenue and Forecast, by Application
11.5.3. Market Revenue and Forecast, by Drug
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology
11.5.4.2. Market Revenue and Forecast, by Application
11.5.4.3. Market Revenue and Forecast, by Drug
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology
11.5.5.2. Market Revenue and Forecast, by Application
11.5.5.3. Market Revenue and Forecast, by Drug
12.1. IBM Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Exscientia
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Deep Genomics
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Cloud Pharmaceuticals, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Microsoft Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. NVIDIA Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Insilico Medicine
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Alphabet Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Atomwise, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Biosymetrics
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Euretos
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. BenevolentAI
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample